Abbott Laboratories Net Profit Margin 2010-2025 | ABT
Current and historical net profit margin for Abbott Laboratories (ABT) from 2010 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue. Abbott Laboratories net profit margin for the three months ending March 31, 2025 was .
| Abbott Laboratories Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2025-03-31 | $42.34B | $13.50B | 31.89% |
| 2024-12-31 | $41.95B | $13.40B | 31.95% |
| 2024-09-30 | $41.22B | $5.77B | 13.99% |
| 2024-06-30 | $40.73B | $5.56B | 13.65% |
| 2024-03-31 | $40.33B | $5.63B | 13.96% |
| 2023-12-31 | $40.11B | $5.72B | 14.27% |
| 2023-09-30 | $39.96B | $5.16B | 12.92% |
| 2023-06-30 | $40.23B | $5.16B | 12.83% |
| 2023-03-31 | $41.51B | $5.80B | 13.98% |
| 2022-12-31 | $43.65B | $6.93B | 15.88% |
| 2022-09-30 | $45.03B | $7.89B | 17.52% |
| 2022-06-30 | $45.55B | $8.55B | 18.78% |
| 2022-03-31 | $44.51B | $7.73B | 17.35% |
| 2021-12-31 | $43.08B | $7.07B | 16.42% |
| 2021-09-30 | $42.31B | $7.24B | 17.12% |
| 2021-06-30 | $40.23B | $6.38B | 15.85% |
| 2021-03-31 | $37.34B | $5.72B | 15.33% |
| 2020-12-31 | $34.61B | $4.50B | 12.99% |
| 2020-09-30 | $32.22B | $3.38B | 10.50% |
| 2020-06-30 | $31.44B | $3.11B | 9.89% |
| 2020-03-31 | $32.10B | $3.58B | 11.15% |
| 2019-12-31 | $31.90B | $3.69B | 11.56% |
| 2019-09-30 | $31.36B | $3.29B | 10.50% |
| 2019-06-30 | $30.94B | $2.90B | 9.36% |
| 2019-03-31 | $30.72B | $2.62B | 8.53% |
| 2018-12-31 | $30.58B | $2.37B | 7.74% |
| 2018-09-30 | $30.40B | $0.89B | 2.91% |
| 2018-06-30 | $29.58B | $0.93B | 3.13% |
| 2018-03-31 | $28.45B | $0.48B | 1.67% |
| 2017-12-31 | $27.39B | $0.48B | 1.74% |
| 2017-09-30 | $25.13B | $2.10B | 8.37% |
| 2017-06-30 | $23.61B | $1.17B | 4.96% |
| 2017-03-31 | $22.30B | $1.50B | 6.74% |
| 2016-12-31 | $20.85B | $1.40B | 6.71% |
| 2016-09-30 | $20.71B | $1.37B | 6.61% |
| 2016-06-30 | $20.56B | $2.28B | 11.08% |
| 2016-03-31 | $20.39B | $2.45B | 12.00% |
| 2015-12-31 | $20.41B | $4.42B | 21.68% |
| 2015-09-30 | $20.57B | $4.56B | 22.17% |
| 2015-06-30 | $20.50B | $4.52B | 22.04% |
| 2015-03-31 | $20.39B | $4.20B | 20.60% |
| 2014-12-31 | $20.25B | $2.28B | 11.28% |
| 2014-09-30 | $18.90B | $1.97B | 10.42% |
| 2014-06-30 | $18.65B | $2.40B | 12.86% |
| 2014-03-31 | $19.03B | $2.41B | 12.65% |
| 2013-12-31 | $19.66B | $2.58B | 13.10% |
| 2013-09-30 | $18.84B | $3.04B | 16.13% |
| 2013-06-30 | $19.28B | $4.02B | 20.83% |
| 2013-03-31 | $19.14B | $5.27B | 27.50% |
| 2012-12-31 | $19.05B | $5.96B | 31.30% |
| 2012-09-30 | $26.24B | $6.53B | 24.88% |
| 2012-06-30 | $30.79B | $4.89B | 15.88% |
| 2012-03-31 | $35.09B | $5.11B | 14.55% |
| 2011-12-31 | $38.85B | $4.73B | 12.17% |
| 2011-09-30 | $38.44B | $4.55B | 11.84% |
| 2011-06-30 | $37.30B | $5.14B | 13.78% |
| 2011-03-31 | $36.51B | $4.49B | 12.29% |
| 2010-12-31 | $35.17B | $4.63B | 13.16% |
| 2010-09-30 | $33.99B | $4.73B | 13.90% |
| 2010-06-30 | $33.08B | $5.31B | 16.07% |
| 2010-03-31 | $31.74B | $5.31B | 16.73% |
| 2009-12-31 | $30.76B | $5.75B | 18.68% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $229.711B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $154.351B | 38.64 |
| Stryker (SYK) | United States | $149.416B | 31.24 |
| EssilorLuxottica (ESLOY) | France | $132.057B | 0.00 |
| Medtronic (MDT) | Ireland | $115.083B | 16.32 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.624B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.474B | 25.39 |
| ResMed (RMD) | United States | $37.259B | 27.99 |
| Agilent Technologies (A) | United States | $34.110B | 22.24 |
| GE HealthCare Technologies (GEHC) | United States | $34.090B | 16.18 |
| Terumo (TRUMY) | Japan | $24.459B | 31.77 |
| Koninklijke Philips (PHG) | Netherlands | $23.149B | 16.24 |
| Insulet (PODD) | United States | $20.550B | 80.67 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.570B | 11.93 |
| Baxter (BAX) | United States | $14.641B | 10.93 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.157B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.825B | 23.75 |
| Lantheus Holdings (LNTH) | United States | $5.747B | 14.50 |
| Prestige Consumer Healthcare (PBH) | United States | $3.776B | 16.87 |
| Perrigo (PRGO) | Ireland | $3.768B | 9.55 |
| Haemonetics (HAE) | United States | $3.683B | 16.77 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.395B | 28.21 |
| ICU Medical (ICUI) | United States | $3.220B | 23.75 |
| QuidelOrtho (QDEL) | United States | $1.952B | 13.42 |
| LeMaitre Vascular (LMAT) | United States | $1.900B | 42.47 |
| AtriCure (ATRC) | United States | $1.550B | 0.00 |
| Acuren (TIC) | United States | $1.455B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.374B | 30.91 |
| Phibro Animal Health (PAHC) | United States | $1.278B | 16.34 |
| AdaptHealth (AHCO) | United States | $1.237B | 12.56 |
| Neogen (NEOG) | United States | $1.133B | 14.50 |
| BioLife Solutions (BLFS) | United States | $1.053B | 0.00 |
| InMode (INMD) | Israel | $0.932B | 9.39 |
| Kestra Medical Technologies (KMTS) | United States | $0.792B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.749B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.680B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.661B | 0.00 |
| Owens & Minor (OMI) | United States | $0.616B | 5.11 |
| Evolus (EOLS) | United States | $0.613B | 0.00 |
| CeriBell (CBLL) | United States | $0.592B | 0.00 |
| Valneva SE (VALN) | France | $0.517B | 0.00 |
| Surmodics (SRDX) | United States | $0.449B | 0.00 |
| SNDL (SNDL) | Canada | $0.415B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.337B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.327B | 12.02 |
| Sanuwave Health (SNWV) | United States | $0.310B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.306B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Quanterix (QTRX) | United States | $0.302B | 0.00 |
| Cerus (CERS) | United States | $0.277B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.266B | 22.40 |
| Aurora Cannabis (ACB) | Canada | $0.257B | 76.33 |
| Sanara MedTech (SMTI) | United States | $0.257B | 0.00 |
| ZimVie (ZIMV) | United States | $0.249B | 11.30 |
| Brainsway (BWAY) | Israel | $0.231B | 61.17 |
| Omeros (OMER) | United States | $0.230B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.230B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.226B | 0.00 |
| Biote (BTMD) | United States | $0.221B | 6.22 |
| Canopy Growth (CGC) | Canada | $0.215B | 0.00 |
| Organigram Global (OGI) | Canada | $0.198B | 0.00 |
| High Tide (HITI) | Canada | $0.195B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.188B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.184B | 15.00 |
| Vireo Growth (VREOF) | United States | $0.162B | 0.00 |
| Exagen (XGN) | United States | $0.151B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.123B | 15.13 |
| TerrAscend (TSNDF) | Canada | $0.115B | 0.00 |
| Fonar (FONR) | United States | $0.101B | 13.05 |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Jin Medical (ZJYL) | China | $0.094B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.092B | 0.00 |
| Veru (VERU) | United States | $0.089B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.083B | 0.00 |
| Apyx Medical (APYX) | United States | $0.074B | 0.00 |
| InterCure (INCR) | Israel | $0.071B | 0.00 |
| Agape ATP (ATPC) | $0.069B | 0.00 | |
| Cytosorbents (CTSO) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Nephros (NEPH) | United States | $0.040B | 54.00 |
| Safety Shot (SHOT) | United States | $0.040B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.038B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 12.87 |
| Allurion Technologies (ALUR) | United States | $0.021B | 0.00 |
| Flora Growth (FLGC) | United States | $0.016B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |